Cogent Biosciences, Inc. Gain (Loss) on Extinguishment of Debt
Cogent Biosciences, Inc. (COGT) reported Gain (Loss) on Extinguishment of Debt of -$7.18 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-02-17
- Cogent Biosciences, Inc. gain (loss) on extinguishment of debt for fiscal 2025 was -$7.18M.
- Cogent Biosciences, Inc. gain (loss) on extinguishment of debt for fiscal 2024 was $0.00.
- Cogent Biosciences, Inc. gain (loss) on extinguishment of debt for fiscal 2023 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|
| 2025-12-31 | -$7.18M 10-K · filed 2026-02-17 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-17 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |